Eli Lilly shares are surging after it posted impressive second-quarter results, helped by a combination of more supply and better pricing for its blockbuster weight loss drugs, Mounjaro and Zepbound, suggesting it might be gaining ground against Novo Nordisk . "Investors were nervous going in and this print would...
Investors want to know whether Eli Lilly is seeing the same pricing pressures on its blockbuster weight loss drug Zepbound that Novo Nordisk experienced with its competing drug Wegovy in the second quarter. Novo Nordisk shocked investors on Wednesday when its latest results fell short of Wall Street's expectations....
Eli Lilly appears to be making as much of its popular obesity and diabetes medicines as it can, but shortages are worsening , putting the company's earnings at risk, analysts say. Tirzepatide is the active ingredient in both Eli Lilly's diabetes treatment Mounjaro and its anti-obesity drug Zepbound. The...